ERTAPENEM NEUROTOXICITY IN PATIENTS WITH KIDNEY INJURY
ERTAPENEM IN KIDNEY INJURY
Keywords:
Ertapenem; seizures; kidney injury
Abstract
Ertapenem, a member of the carbapenem group of antibiotics, is a broad-spectrum antibiotic that is effective against multidrug-resistant gram-positive and gram-negative infections. One of the most serious side effects of ertapenem is neurotoxicity in patients with acute or chronic kidney injury. Various clinical conditions such as seizures, hallucinations, delirium, confusion, and nystagmus may occur. Previous history of cerebral pathologies is a known risk factor for ertapenem-associated neurotoxicity. Immediate discontinuation of treatment is the first intervention. Although the symptoms usually resolve rapidly, prolonged cases have also been reported. Monitoring neurological status is a must in such patients.
References
References
1. Deshayes S, Coquerel A, Verdon R. Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review. Drug Saf. 2017;40(12):1171-1198.
2. Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011; 31(4): 408–423.
3. Lee Y-C, Huang Y-J, Hung M-C, Hung S-C, Hsiao C-Y, Cho H-L, et al. Risk factors associated with the development of seizures among adult patients treated with ertapenem: A matched case-control study. PLoS ONE; 2017: 12(7): e0182046.
4. Molnar GP, Stephens KJ, George LV, Stewart JT. A critical interaction between ertapenem and valproic acid. J Clin Psychopharmacol. 2015; 35(3): 348-350.
5. ALBERTO E. FICA, NANCY J. ABUSADA. Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. Scand J Infect Dis. 2008; 40(11-12): 983-985.
1. Deshayes S, Coquerel A, Verdon R. Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review. Drug Saf. 2017;40(12):1171-1198.
2. Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011; 31(4): 408–423.
3. Lee Y-C, Huang Y-J, Hung M-C, Hung S-C, Hsiao C-Y, Cho H-L, et al. Risk factors associated with the development of seizures among adult patients treated with ertapenem: A matched case-control study. PLoS ONE; 2017: 12(7): e0182046.
4. Molnar GP, Stephens KJ, George LV, Stewart JT. A critical interaction between ertapenem and valproic acid. J Clin Psychopharmacol. 2015; 35(3): 348-350.
5. ALBERTO E. FICA, NANCY J. ABUSADA. Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. Scand J Infect Dis. 2008; 40(11-12): 983-985.
Published
2025/12/22
Section
Prikaz slučaja / Case report